scholarly journals Effect of Oral Care Gel for Burning Mouth Syndrome in a Patient with Hepatitis C: A Case Report

2017 ◽  
Vol 11 (2) ◽  
pp. 480-487 ◽  
Author(s):  
Yumiko Nagao ◽  
Yuji Kawahigashi ◽  
Kanae Kimura ◽  
Michio Sata
Keyword(s):  
Hepatitis C ◽  
Oral Care ◽  
Depressive Mood ◽  
Virologic Response ◽  
Burning Mouth Syndrome ◽  
Burning Sensation ◽  
Therapeutic Effects ◽  
Number Of Patients ◽  
Long Term Follow Up ◽  
Burning Mouth

Burning mouth syndrome (BMS) is a burning sensation in the mouth with no underlying dental or medical cause. To date, there is no satisfactory treatment for BMS. Herein, we present the case of a 42-year-old female presenting with hepatitis C virus infection along with BMS. Despite two interferon therapies and a sustained virologic response, the discomfort in her oral mucosa persisted. At the age of 51, the patient complained of burning sensation and tingling pain in the tongue; a thin layer of REFRECARE-H®, an oral care gel (therapeutic dentifrice), was applied on the oral membrane after each meal for 60 days. Application of REFRECARE-H® decreased the various symptoms including tingling pain, oral discomfort, breath odor, sleep disorder, depressive mood, and jitteriness. The improvement in quality of life continued for 30 days after application of the gel. These findings indicate that REFRECARE-H® may be effective in reducing the symptoms associated with BMS. Long-term follow-up studies with larger number of patients are required to elucidate the therapeutic effects of this gel.

Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response

2019 ◽  
Author(s):  
Hidenori Toyoda ◽  
Toshifumi Tada ◽  
Satoshi Yasuda ◽  
Kazuyuki Mizuno ◽  
Takanori Ito ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Sustained Virologic Response ◽  
Dynamic Assessment ◽  
Predictive Ability ◽  
Virologic Response ◽  
Hcv Therapy ◽  
Number Of Patients ◽  
Advanced Liver Fibrosis

Abstract Background Liver fibrosis is an important risk factor for the development of hepatocellular carcinoma (HCC) after sustained virologic response (SVR) in patients with persistent hepatitis C virus (HCV) infection. However, as the degree of liver fibrosis changes following the eradication of HCV after SVR, it is unclear whether the prediction of HCC development based on liver fibrosis at baseline remains valid. Methods In 522 patients who achieved SVR by interferon-based anti-HCV therapy, the Fibrosis-4 Index for Liver Fibrosis (FIB-4 index) was updated annually by recalculation based on laboratory values after SVR. The incidence of HCC was reassessed annually based on the updated FIB-4 index. Results The percentage of patients with mild liver fibrosis (FIB-4 index <1.45) increased annually after SVR, whereas the percentage of patients with advanced liver fibrosis (FIB-4 index ≥3.25) decreased. The incidences of HCC based on the FIB-4 index remained constant between the time of SVR and subsequent annual updates. No patients developed HCC after SVR if the FIB-4 index decreased to <1.45. Conclusions The FIB-4 index retained its predictive ability for the risk of HCC when recalculated after SVR, despite the decrease in patients with high FIB-4 index values. Dynamic assessment of the FIB-4 index can be useful in the surveillance of HCC after SVR. Patients with a FIB-4 index <1.45 did not develop HCC even by the regression from advanced fibrosis after SVR. Further studies will be necessary to confirm these findings, which may result in a decrease in the number of patients in whom surveillance is required.

Update on Burning Mouth Syndrome: Overview and Patient Management

2003 ◽  
Vol 14 (4) ◽  
pp. 275-291 ◽  
Author(s):  
A. Scala ◽  
L. Checchi ◽  
M. Montevecchi ◽  
I. Marini ◽  
M.A. Giamberardino
Keyword(s):  
Chronic Pain ◽  
Patient Management ◽  
Current Knowledge ◽  
Pain Syndrome ◽  
Burning Mouth Syndrome ◽  
Nerve Damage ◽  
Hormonal Changes ◽  
Oral Diseases ◽  
Number Of Patients ◽  
Burning Mouth

Burning Mouth Syndrome (BMS) is a chronic pain syndrome that mainly affects middle-aged/old women with hormonal changes or psychological disorders. This condition is probably of multifactorial origin, often idiopathic, and its etiopathogenesis remains largely enigmatic. The present paper discusses several aspects of BMS, updates current knowledge, and provides guidelines for patient management. There is no consensus on the diagnosis and classification of BMS. The etiopathogenesis seems to be complex and in a large number of patients probably involves interactions among local, systemic, and/or psychogenic factors. In the remaining cases, new interesting associations have recently emerged between BMS and either peripheral nerve damage or dopaminergic system disorders, emphasizing the neuropathic background in BMS. Based on these recent data, we have introduced the concepts of “primary” (idiopathic) and “secondary” (resulting from identified precipitating factors) BMS, since this allows for a more systematic approach to patient management. The latter starts with a differential diagnosis based on the exclusion of both other orofacial chronic pain conditions and painful oral diseases exhibiting muco-sal lesions. However, the occurrence of overlapping/overwhelming oral mucosal pathologies, such as infections, may cause difficulties in the diagnosis ("complicated BMS"). BMS treatment is still unsatisfactory, and there is no definitive cure. As a result, a multidisciplinary approach is required to bring the condition under better control. Importantly, BMS patients should be offered regular follow-up during the symptomatic periods and psychological support for alleviating the psychogenic component of the pain. More research is necessary to confirm the association between BMS and systemic disorders, as well as to investigate possible pathogenic mechanisms involving potential nerve damage. If this goal is to be achieved, a uniform definition of BMS and strict criteria for its classification are mandatory.

scholarly journals Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan

2017 ◽  
Vol 62 (2) ◽  
Author(s):  
Preethi Krishnan ◽  
Gretja Schnell ◽  
Rakesh Tripathi ◽  
Jill Beyer ◽  
Thomas Reisch ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virologic Failure ◽  
Virologic Response ◽  
Fixed Dose ◽  
Resistance Testing ◽  
Combination Regimen ◽  
Resistance Analysis ◽  
Number Of Patients ◽  
The Impact

ABSTRACT Glecaprevir and pibrentasvir are hepatitis C virus (HCV) pangenotypic inhibitors targeting NS3/4A protease and NS5A, respectively. This once-daily, fixed-dose combination regimen demonstrated high sustained virologic response 12 weeks postdosing (SVR12) rates in CERTAIN-1 and CERTAIN-2 studies in Japanese HCV-infected patients, with a low virologic failure rate (1.2%). There were no virologic failures among direct-acting antiviral (DAA)-treatment-naive genotype 1a (GT1a) (n = 4)-, GT1b (n = 128)-, and GT2 (n = 97)-infected noncirrhotic patients treated for 8 weeks or among GT1b (n = 38)- or GT2 (n = 20)-infected patients with compensated cirrhosis treated for 12 weeks. Two of 33 DAA-experienced and 2 of 12 GT3-infected patients treated for 12 weeks experienced virologic failure. Pooled resistance analysis, grouped by HCV subtype, treatment duration, prior treatment experience, and cirrhosis status, was conducted. Among DAA-naive GT1b-infected patients, the baseline prevalence of NS3-D168E was 1.2%, that of NS5A-L31M was 3.6%, and that of NS5A-Y93H was 17.6%. Baseline polymorphisms in NS3 or NS5A were less prevalent in GT2, with the exception of the common L/M31 polymorphism in NS5A. Among DAA-experienced GT1b-infected patients (30/32 daclatasvir plus asunaprevir-experienced patients), the baseline prevalence of NS3-D168E/T/V was 48.4%, that of NS5A-L31F/I/M/V was 81.3%, that of the NS5A P32deletion was 6.3%, and that of NS5A-Y93H was 59.4%. Common baseline polymorphisms in NS3 and/or NS5A had no impact on treatment outcomes in GT1- and GT2-infected patients; the impact on GT3-infected patients could not be assessed due to the enrollment of patients infected with diverse subtypes and the limited number of patients. The glecaprevir-pibrentasvir combination regimen allows a simplified treatment option without the need for HCV subtyping or baseline resistance testing for DAA-naive GT1- or GT2-infected patients. (The CERTAIN-1 and CERTAIN-2 studies have been registered at ClinicalTrials.gov under identifiers NCT02707952 and NCT02723084, respectively.)

Burning mouth syndrome- An Oral Physicians Dilemma

2017 ◽  
Vol 6 (4) ◽  
Author(s):  
N. Kavitaa
Keyword(s):  
Oral Mucosa ◽  
Facial Pain ◽  
Clinical Signs ◽  
Burning Mouth Syndrome ◽  
Burning Sensation ◽  
Pain Disorder ◽  
Treatment Modalities ◽  
Clear Cut ◽  
Burning Mouth

Burning Mouth Syndrome (BMS) is a chronic oro-facial pain disorder that affects both genders, but predominately with higher female predilection. The condition is characterized by burning sensation present over the oral mucosa and tongue, with no definable clinical signs. The etiology for BMS is not clear cut, so does the quality of treating the condition is hampered. The present paper reviews the etiology, pathophysiology, diagnostic criteria’s and treatment modalities in treating BMS which poses as a great challenge for the oral physicians.

scholarly journals Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon

2010 ◽  
Vol 14 (4) ◽  
pp. 330-334 ◽  
Author(s):  
Sandro da Costa Ferreira ◽  
Marcos de Vasconcelos Carneiro ◽  
Fernanda Fernandes Souza ◽  
Andreza Corrêa Teixeira ◽  
Marcia Guimarães Villanova ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Sustained Virologic Response ◽  
Virologic Response ◽  
Long Term Follow Up

scholarly journals Burning Mouth Syndrome: Case Reports

2020 ◽  
Vol 5 (4) ◽  
pp. 76-78
Author(s):  
Catarina da Costa Campos ◽  
Maria do Céu Ferreira ◽  
Joana Mesquita
Keyword(s):  
Psychological Factors ◽  
Case Reports ◽  
Burning Mouth Syndrome ◽  
Burning Sensation ◽  
Therapeutic Approaches ◽  
Physiological Factors ◽  
Common Chronic Disease ◽  
Clinically Normal ◽  
Nosological Entity ◽  
Burning Mouth

Burning mouth syndrome (BMS) is a relatively common chronic disease of unclear etiopathogenesis. It is defined as a distinctive nosological entity that includes all forms of burning sensation in the mouth, including stinging sensation or pain, in association with an oral mucosa that appears clinically normal, in the absence of local or systemic diseases. It was hypothesized that psychological factors could influence its appearance, but also physiological factors, with some authors suggesting a neuropathic etiology. Regarding the treatment of BMS, benefits were found in individual or group psychotherapy, as well as in psychopharmacological interventions, however its current therapeutic approach is not completely satisfactory. In this paper we describe two cases of BMS and discuss the possible etiopathogenesis and current therapeutic approaches.

scholarly journals A Case of Vestibular Schwannoma with Oral Burning Sensation: Surgical Complication or Burning Mouth Syndrome?

2020 ◽  
Author(s):  
Takayuki Suga ◽  
Miho Takenoshita ◽  
Trang T.H Tu ◽  
Chaoli Hong ◽  
Chihiro Takao ◽  
...  
Keyword(s):  
Vestibular Schwannoma ◽  
Facial Pain ◽  
Somatic Symptom ◽  
Bitter Taste ◽  
Surgical Complication ◽  
Exceptional Case ◽  
Burning Mouth Syndrome ◽  
Burning Sensation ◽  
Burning Mouth ◽  
Oral Burning

Abstract Background: Vestibular schwannoma (VS) or acoustic neuroma is a benign brain tumor. Despite improvements in surgical technique, the removal of VS is related to some complications of which the recovery is difficult and sometimes lead to permanent deficits. About 10.7% of complication of vestibular schwannoma surgery is reported to affect facial or tongue area, including numbness of pain, which is similar to a typical symptom of burning mouth syndrome (BMS). However, up to our knowledge, there is no documented case of BMS either comorbid with vestibular schwannoma or occur due to surgery complications. Clinical Presentation: A 46-year-old woman complained about left-sided facial pain, a burning sensation on the left side of her tongue and maxilla, and a spontaneous bitter taste. Four years before her first visit to our clinic, left-sided facial pain and burning sensation on the left side of the tongue suddenly became severe. She visited a neurosurgeon and VS was found in the left cerebellopontine angle. After the tumor was removed, facial pain, burning sensation of the tongue, and bitter taste improved simultaneously but quickly recurred after a while. The patient had a panic attack because of severe pain and started visiting a psychiatrist. The psychiatrist diagnosed her as having somatic symptom disorder and depression, prescribing sertraline 100 mg, zolpidem 5 mg, and lorazepam 1.0 mg and referred her to our clinic. At the first visit, no abnormal intraoral nor extraoral findings were detected. Based on the characteristics of the pain, we made a diagnose of BMS. Amitriptyline was initiated at 10 mg/day and increased to 30 m. Within 1.5 months, the pain and burning sensation of the tongue and maxilla almost remitted completely, whereas bitter taste showed moderate improvement. Conclusions: Our case suggests there might be an exceptional case in which BMS and VS can occur simultaneously. Specifically, an oral burning sensation and dysgeusia after VS surgery are not always a case of surgical complication or untreatable.

scholarly journals Burning Mouth Syndrome pada wanita Menopause dengan Hiposalivasi, Coated Tongue dan Gangguan Pengecapan serta Penatalaksanaannya

2012 ◽  
Vol 19 (1) ◽  
pp. 82
Author(s):  
Sri Hadiati
Keyword(s):  
Oral Cavity ◽  
Postmenopausal Women ◽  
Vitamin B1 ◽  
Burning Mouth Syndrome ◽  
Burning Sensation ◽  
Chewing Gum ◽  
Affected Patient ◽  
Burning Mouth ◽  
Oral Burning

Blackground: Burning mouth syndrome (BMS) is a disorder that is characterized by a burning sensation of the oral cavity in the absence of visible local or systemic abnormalities. Affected patient often present with multiple oral complaints, including burning, dryness and taste alterations. The exact cause of burning mouth syndrome often is difficult to pin point. Conditions that have been reported in association with burning mouth syndrome include menopause, hyposlivation, coated tongue, taste alterations and psychologic condition. Objective: To report a case of burning mouth syndrome in postmenopausal women with hyposalivation, coated tongue, taste alterations and psychologic condition and its management. Case and management: a case of burning mouth syndrome in women with menopause, hyposalivation, coated tongue, and taste alterations, was managed effectively by gabapentin 100mg, probiotic chewing gum, diazepam 2mg and vitamin B1, B6, B12. Conclusion: Oral burning appears to be most prevalent in postmenopausal women often present with multiple oral complaints, including burning, dryness and taste alterations, in this case was managed effectively by gabapentin 100mg, prebiotic chewing gum, diazepam 2mg and vitamin B1, B6, B12.

scholarly journals Burning Mouth Syndrome: A Review of the Etiopathologic Factors and Management

2016 ◽  
Vol 17 (2) ◽  
pp. 171-176 ◽  
Author(s):  
Sajith Vellappally
Keyword(s):  
Blood Test ◽  
Multidisciplinary Approach ◽  
Current Knowledge ◽  
Burning Mouth Syndrome ◽  
Number Of Patients ◽  
Oral Mucosal Lesions ◽  
Mucosal Lesions ◽  
Burning Mouth ◽  
Etiological Agents ◽  
Burning Mouth Sensation

ABSTRACT Burning mouth syndrome (BMS) is characterized by pain in the mouth with or with no inflammatory signs and no specific lesions. Synonyms found in literature include glossodynia, oral dysesthesia, glossopyrosis, glossalgia, stomatopyrosis, and stomatodynia. Burning mouth syndrome generally presents as a triad: Mouth pain, alteration in taste, and altered salivation, in the absence of visible mucosal lesions in the mouth. The syndrome generally manifests spontaneously, and the discomfort is typically of a continuous nature but increases in intensity during evening and at night. The etiopathogenesis seems to be complex and in a large number of patients probably involves interactions among local, systemic, and/or psychogenic factors. The differential diagnosis requires the exclusion of oral mucosal lesions or blood test alterations that can produce burning mouth sensation. Management is always based on the etiological agents involved. If burning persists after local or systemic conditions are treated, then treatment is aimed at controlling neuropathic symptoms. Treatment of BMS is still unsatisfactory, and there is no definitive cure. As a result, a multidisciplinary approach is required to bring the condition under better control. The aim of this review was to discuss several aspects of BMS, update current knowledge, and provide guidelines for patient management. How to cite this article Vellappallay S. Burning Mouth Syndrome: A Review of the Etiopathologic Factors and Management. J Contemp Dent Pract 2016;17(2):171-176.

scholarly journals Burning mouth syndrome caused by xerostomia secondary to amlodipine

2020 ◽  
Vol 53 (4) ◽  
pp. 187
Author(s):  
Tengku Natasha Eleena Binti Tengku Ahmad Noor
Keyword(s):  
Oral Cavity ◽  
Oral Hygiene ◽  
Health Care Professionals ◽  
Adverse Drug Events ◽  
Burning Mouth Syndrome ◽  
Burning Sensation ◽  
Dry Mouth ◽  
Protective Function ◽  
Burning Mouth ◽  
Oral Hygiene Instructions

Background: Xerostomia, generally referred to as dry mouth, has been identified as a side effect of more than 1,800 drugs from more than 80 groups. This condition is frequently unrecognised and untreated but may affect patients’ quality of life and cause problems with oral and medical health, including burning mouth syndrome (BMS). Purpose: The purpose of this case is to discuss how to manage a patient with BMS caused by xerostomia secondary to medication that has been taken by the patient. Case: We reported that a 45-year-old male military officer from the Royal Malaysian Air Force came to Kuching Armed Forces Dental Clinic with dry mouth and a burning sensation since he started taking 10 mg of amlodipine due to his hypertension. After a thorough physical and history examination, we made a diagnosis of burning mouth syndrome (BMS) caused by xerostomia secondary to amlodipine. Case Management: Oral hygiene instructions, diet advice and prescription of Oral7 mouthwash has been given to reduce the symptoms of BMS. The patient has been referred to the general practitioner to reduce his amlodipine dosage from 10 mg to 5 mg (OD) in order to prevent xerostomia, and oral hygiene instructions have been given. A review after two weeks showed significant changes in the oral cavity, and the patient was satisfied as he is no longer feeling the burning sensation and can enjoy his food without feeling difficulty in chewing and swallowing. Conclusion: Adverse drug events are normal in the oral cavity and may have a number of clinical presentations such as xerostomia. Xerostomia can cause many implications as saliva helps in maintaining oral mucosa and has a protective function. The signs of adverse drug incidents in the oral cavity should be identified to oral health care professionals.

Sign in / Sign up

Export Citation Format

Share Document